A plasma cell variant of castleman's disease treated successfully with cimetidine.case report and review of the literature

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 545-548

  Barbounis, V ^a   Efremidis, A ^a  

^a Regional Anticancer Oncology Hospital of Athens 'St Savvas'   (Greece)

Author keywords

Castleman's disease; Cimetidine; Plasma cell variant

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; DRUG EFFICACY; HUMAN; INFLAMMATION; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL;

ADULT; CIMETIDINE; GIANT LYMPH NODE HYPERPLASIA; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; PLASMA CELLS;

EID: 0029870990     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Castleman B, Iverson L, Menendez VP: Localized mediastinal lymph node hyperplasia resembling thymona Cancer 9: 822-830, 1956.
2. Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasmacell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29: 670-683, 1972.
3. Frizzera G: Castleman's diseare and related disorders. Semin Diagn Pathol 5(4) 346-364, 1988.
4. Gherardi R, Zuber M, Viard JP: (Dysglobulinemic Neuropathies). Rev Neurol 144 (6-7): 391-408, 1988.
5. Rolon PG, Andouin J, Diebolo J, et al: Multicentric angiofollicular lymph node hyperplasia associated with a solitary osteolytic costal IgG lambda myeloma POEMS syndrome in a South American (Paraguaycin) patients. Pathol Res Pract 185 (4): 468-479 1989.
6. Delmer A, Karmochkine M, Le Toyrneau A, et al: Maladie de Castleman (Hyperplasie lymphoide angiofolliculaire): Polymorfism clinique biologique et evolutife. A propos de 4 observations. Ann Med Interne (Paris) 141 (2): 123-128, 1990.
7. Nakanishi T: Crow-Fukase syndrome. Rinsho Shinkeigaku 29 (12): 1477-1484, 1990.
8. Donaghy M, Hall P, Gawler J, et al: Peripheral neurophathy associated with Castleman's disease. J Neurol Sci 89 (2-3): 353-367, 1989.
9. Pavlidis NA, Skopouli FN, Bai MC, Bourantas CL: A successfully treated case of multicentric angiofollicular hyperplasia with oral chemotherapy (Castleman's disease). Med Pediatr Oncol 18 (4): 333-335, 1990.
10. Brant SJ, Bodine DM, Dunbar CE, Nienhuts AW: Dysregulated Interleukin-6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 86 (2): 592-599, 1990.
11. Yoshizaki K, Matsuda T, Nishimoto N, et al: Pathogenic significance of interleukin-76 (IL-6/BSF-2) in Castleman's disease. Blood 7(4): 1360-1367, 1989.
12. Yoshizaki K, Matsuda T, Nishimoto N, et al. Rinsho Byori 38(4): 375-379, 1990.
13. Efremidis AP, Giannopoulos Z, Tournantonis A: Letter to the Editor. N Eng J Med 313: 265, 1985.
14. While WB, Ballow M: Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia N Engl J Med 312: 198-202, 1985.
15. Rocklin RC, Greineder D, Littman GH, et al: Modulation of cellular immune function in vitro by histamine receptor-bearing lymphocytes mechanism of action. Cell Immunol 37: 162-173, 1978.
16. Gilfford RRM, Hatfield SM, Schmidtke JR: Cimetidine-induced augmentation of human lymphocyte blastogenesis by mitogen bacterial antigen and alloantigen. Transplantation 29: 143-148, 1980.
17. Mavligit GM, Calvo BD III, Patt YZ, et al: Immune restoration and/or augmentation of local xenogenic graft versus host reaction by cimetidine in vitro J Immunol, 126: 2272-2274, 1981.
18. Palacio SR, and Alarcon-Segovia D: Cimetidine abrogates suppressor T-cell function in vitro. Immunology Letter: 3: 33-37, 1981.
19. 2) receptor antagonists. Immunol 132 (6): 3054-3057, 1984.
20. Jonzzo JL, Sans MW Jr, Jegasothy BV, et al: Cimetidine as an immunomodulator: Chronic mycocutaneous candidiasis as a model. Annals Internal Medicine 92: 192-195, 1980
21. Brockmeyer NH, Krevzfelder E, Bluhm C, et al. Immunomodulation of cimetidine in healthy volunteers. Klin Wochenschr 67: 26-30, 1989.